Novartis UK's response to the Government's Industrial Strategy
Nov 27, 2017
Novartis welcomes today’s announcement from Government on Industrial Strategy. This is an encouraging step towards realising the ambitious Life Sciences Industrial Strategy (LSIS), announced in the summer, which recognises and seeks to bolster the importance of our sector for a successful post-Brexit Britain. If the recommendations of the LSIS are implemented, the UK has the potential to be a world leading force in science, healthcare and medical innovation, and one of the best places in the world for discovering, developing and adopting new medicines for UK patients.
Novartis is the leading commercial sponsor of clinical research within the UK and spends almost £40 million a year on R&D here. Novartis is also the leading pharmaceutical company investing in joint working with the NHS, where both the company and the NHS pool resources and expertise to improve healthcare services, and patient experiences and outcomes. Novartis continues to invest in these areas which contributes to making efficiencies within the NHS and building world leading clinical expertise across a number of disease areas.
Novartis looks forward to a new, voluntary agreement on medicines pricing being negotiated - which should see UK patients get greater access to medical innovations that may extend or improve their lives – and to more clarity of post-Brexit arrangements for our industry, which will bring more certainty for investment decisions being made across our industry. Novartis will continue to explore options for future collaborations and to optimize our footprint in the UK, as we do in all major markets.